Augmented Expansion of Treg Cells From Healthy and Autoimmune Subjects <i>via</i> Adult Progenitor Cell Co-Culture.

ABSTRACT: Recent clinical experience has demonstrated that adoptive regulatory T (Treg) cell therapy is a safe and feasible strategy to suppress immunopathology via induction of host tolerance to allo- and autoantigens. However, clinical trials continue to be compromised due to an inability to manufacture a sufficient Treg cell dose. Multipotent adult progenitor cells (MAPC^Ⓡ) promote Treg cell differentiation in vitro, suggesting they may be repurposed to enhance ex vivo expansion of Tregs for adoptive cellular therapy. Here, we use a Good Manufacturing Practice (GMP) compatible Treg expansion platform to demonstrate that MAPC cell-co-cultured Tregs (MulTreg) exhibit a log-fold increase in yield across two independent cohorts, reducing time to target dose by an averag

SUBMITTER: Reading JL 

PROVIDER: S-EPMC8442662 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature